Suchbegriffe: IMMUNE CHECKPOINT INHIBITORS - THERAPEUTIC USE , . Treffer: 2
Barth, DA; Stanzer, S; Spiegelberg, JA; Bauernhofer, T; Absenger, G; Szkandera, J; Gerger, A; Smolle, MA; Hutterer, GC; Ahyai, SA; Madl, T; Posch, F; Riedl, JM; Klec, C; Jost, PJ; Kargl, J; Stradner, MH; Pichler, M
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Front Immunol. 2022; 13: 840207
Doi: 10.3389/fimmu.2022.840207
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Hecht, M; Eckstein, M; Rutzner, S; von, der, Grün, J; Illmer, T; Klautke, G; Laban, S; Hautmann, MG; Brunner, TB; Tamaskovics, B; Hinke, A; Zhou, JG; Frey, B; Donaubauer, AJ; Becker, I; Semrau, S; Hartmann, A; Balermpas, P; Budach, W; Gaipl, US; Iro, H; Gostian, AO; Fietkau, R
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer.
J Immunother Cancer. 2022; 10(1):
Doi: 10.1136/jitc-2021-003747
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG